baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

IPSEN S.A. PORT. EO 1/ FR0010259150 /

09/11/2024 13:00:33	Chg. 0.00	Volume	Bid13:00:33	Ask13:00:33	Market Capitalization	Dividend Y.	P/E Ratio
109.80EUR	0.00%	- Turnover: -	109.80Bid Size: -	111.10Ask Size: -	9.24 bill.EUR	1.09%	14.16

GlobeNewswire 26/07 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...

GlobeNewswire 25/07 Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...

GlobeNewswire 25/07 Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...

GlobeNewswire 11/07 Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...

GlobeNewswire 02/07 Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...

GlobeNewswire 10/06 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...

GlobeNewswire 07/06 Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...

GlobeNewswire 06/06 Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

GlobeNewswire 05/06 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...

GlobeNewswire 02/05 Ipsen appoints Keira Driansky as EVP, President of North America

GlobeNewswire 24/04 Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...

GlobeNewswire 22/04 Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...

GlobeNewswire 02/04 Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...

GlobeNewswire 13/02 Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...

GlobeNewswire 08/02 Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

GlobeNewswire 07/12/2023 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...

GlobeNewswire 07/12/2023 Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...

GlobeNewswire 13/11/2023 Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...

GlobeNewswire 26/10/2023 Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidan...

GlobeNewswire 23/10/2023 Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome

GlobeNewswire 03/10/2023 Ipsen updates on QM-1114 regulatory process

GlobeNewswire 04/09/2023 Ipsen nominates Pascal Touchon to its Board of Directors as new independent director

GlobeNewswire 01/09/2023 Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet

GlobeNewswire 21/08/2023 Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Caboza...

GlobeNewswire 16/08/2023 US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people w...

IPSEN S.A. PORT. EO 1/ FR0010259150 /

If you wish to receive reply to your feedback, please provide your email address.